Description:
Rybelsus® 7 mg is a prescription oral tablet containing semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. It is designed to improve blood sugar control when used in conjunction with diet and exercise.
Key Features:
-
Active Ingredient: Semaglutide 7 mg
-
Formulation: Oral tablet
-
Drug Class: GLP-1 receptor agonist
-
Use: Improves glycemic control in adults with type 2 diabetes
Clinical Use:
Rybelsus 7 mg is typically prescribed after 30 days of initiating therapy with Rybelsus 3 mg, as part of a titration plan to minimize gastrointestinal side effects. It may be continued as a maintenance dose or increased to 14 mg based on clinical response.
Mechanism of Action:
Semaglutide mimics the body’s natural GLP-1 hormone, stimulating insulin release in response to elevated blood glucose levels, reducing glucagon secretion, and slowing gastric emptying. This helps in regulating blood sugar levels and may support weight management.
Dosage & Administration:
-
Take once daily, at the same time each day
-
Take on an empty stomach, with no more than 4 oz (120 mL) of plain water
-
Wait at least 30 minutes before eating, drinking, or taking other oral medications
Benefits:
-
Oral, non-injectable GLP-1 therapy
-
Supports reduction in HbA1c levels
-
May contribute to modest weight loss
-
Can be used as monotherapy or in combination with other antidiabetic agents
Safety Information:
-
Not indicated for type 1 diabetes or diabetic ketoacidosis
-
Do not use if you or your family have a history of medullary thyroid carcinoma (MTC) or MEN 2
-
Common side effects include nausea, vomiting, abdominal pain, diarrhea, and decreased appetite
-
Use with caution in combination with insulin or insulin secretagogues due to risk of hypoglycemia
Storage:
Store at controlled room temperature: 20°C to 25°C (68°F to 77°F). Keep in original packaging until use to protect from moisture.
Note: Always use under the supervision of a licensed healthcare provider.
